FSN Capital in market with European multi-asset continuation fund process
The companies involved are housed in FSN Capital V, which closed in 2016 on €1bn, Secondaries Investor understands.
LPs watch Tiger’s secondaries deal as opportunity to hammer VCs on valuations
If bids come in at a steep discount, some LPs are ready to use that data point to question other VCs invested in the same assets about their valuations and why they are not writing them down.
Centre Partners closes deal that extends hold over IMA, Sun Orchard
Several deals across the mid-market have closed recently and market professionals see continued vibrancy at this smaller level of secondaries.
Multi-asset continuation fund by design: One Equity’s $1bn CV
The transaction, which saw AlpInvest and HarbourVest as co-leads, was oversubscribed with One Equity having to turn investors away and cut back its existing investors.
Presidio extends hold on semiconductor testing company amid huge industry growth
Presidio saw an opportunity to extend its hold over Elevate as it continues to implement its growth plan that includes further spending and future acquisitions.
GM pension shops $1bn portfolio of private equity fund stakes
LP sales were expected to kick off a resumption of robust secondaries activity after a slowdown late last year, with external factors such as the collapse of Silicon Valley Bank keeping activity muted.
TPG emerges as co-lead on Oakley’s €1.2bn single-asset continuation fund deal
Oakley is seeking to continue its hold of German university group IU Group, which it initially backed in 2017.
Secondaries Investor Advisory Survey 2023: Advisers choosey with mandates in choppy market
The average number of secondaries transactions advised on sat at 24 in a year where overall secondaries market volume was estimated at around $110bn.
Oakley seeks more than €1bn to continue hold on German university group
Oakley acquired a majority stake in IU Group in 2017 via €800m Oakley Capital Private Equity III fund, alongside a number of underlying Fund III investors.
Kaiser Permanente’s $6bn secondaries sale mostly done
Pent-up demand among sellers facing liquidity pressures and looking to rebalance overexposure issues is expected to bring more processes to market, though later this year.